These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35130368)

  • 21. Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20.
    Nosyk B; Kurz M; Guerra-Alejos BC; Piske M; Dale L; Min JE
    Addiction; 2023 Jul; 118(7):1376-1380. PubMed ID: 36772838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study.
    Conway A; Marshall AD; Crawford S; Hayllar J; Grebely J; Treloar C
    Implement Sci; 2023 Jun; 18(1):22. PubMed ID: 37296448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Opioid Agonist Therapy (OAT) for opioid dependency].
    Köck P; Strasser J
    Ther Umsch; 2020; 77(1):29-36. PubMed ID: 32486990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 30. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.
    Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B
    Addiction; 2021 Jun; 116(6):1482-1494. PubMed ID: 33067836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
    Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
    Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Bojko MJ; Madden L; Filippovich S; Dvoriak S; Altice FL
    Int J Drug Policy; 2017 Jul; 45():56-63. PubMed ID: 28628853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
    Winstock AR; Lea T; Sheridan J
    Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.
    Durand L; Boland F; Harnedy N; Delargy Í; Scully M; Bourke M; Ebbitt W; Otero Vázquez M; Keenan E; Cousins G
    J Subst Use Addict Treat; 2023 Jun; 149():209029. PubMed ID: 37003538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim opioid agonist treatment for opioid addiction: a systematic review.
    Samsó Jofra L; Puig T; Solà I; Trujols J
    Harm Reduct J; 2022 Jan; 19(1):7. PubMed ID: 35090475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.